Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain

References

• Gureje O, Von KM, Simon GE, et al. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998;280:147-51
   PubMed Web of Science ®Google Scholar
• Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med 2009;169:251-58
   PubMed Web of Science ®Google Scholar
• Luo X, Pietrobon R, Sun SX, et al. Estimates and patterns of direct health care expenditures among individuals with back pain in the United States. Spine 2004;29:79-86
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54
   PubMed Web of Science ®Google Scholar
• Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007;147:505-14
   PubMed Web of Science ®Google Scholar
• Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003;63:17-32
   PubMed Web of Science ®Google Scholar
• Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997;14:63-73
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Miaskowski C, Dodd MJ, West C, et al. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol 2001;19:4275-79
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006;7:583-91
   PubMed Web of Science ®Google Scholar
• Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007;100:1028-36
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther 2001;8:181-6
   PubMedGoogle Scholar
• Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother 2006;40:1327-35
   PubMed Web of Science ®Google Scholar
• Gupta S, Sathyan G. Providing constant analgesia with OROS hydromorphone. J Pain Symptom Manage 2007;33(2 Suppl):S19-24
   Web of Science ®Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
   PubMed Web of Science ®Google Scholar
• Angst MS, Drover DR, Lotsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001;94:63-73
   PubMed Web of Science ®Google Scholar
• Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97:827-36
   PubMed Web of Science ®Google Scholar
• Sathyan G, Xu E, Thipphawong J, et al. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol 2007;7:3
   PubMedGoogle Scholar
• Hale M, Tudor IC, Khanna S, et al. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. Clin Ther 2007;29:874-88
   PubMed Web of Science ®Google Scholar
• Wallace M, Skowronski R, Khanna S, et al. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007;23:981-89
   PubMed Web of Science ®Google Scholar
• Wallace M, Rauck RL, Moulin D, et al. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract 2007;61:1671-6
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005;29:S57-66
   PubMed Web of Science ®Google Scholar
• Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003;25:169-78
   PubMed Web of Science ®Google Scholar
• Farrar JT, Young JP, Jr LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics. Focus on methodology. Clin J Pain 2009;25:797-807
   PubMed Web of Science ®Google Scholar
• Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80
   PubMed Web of Science ®Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7:R1046-51
   PubMed Web of Science ®Google Scholar
• Lennens HJ, Wada DR, Munera C, et al. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials 2006;27:165-73
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Deery S, Moore A, et al. Enriched enrolment with randomized withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008;135:217-220
   PubMed Web of Science ®Google Scholar